LENZ Therapeutics (LENZ) EBITDA Margin (2025 - 2026)

LENZ Therapeutics (LENZ) posted quarterly EBITDA Margin of 2321.67% for Q1 2026, down 854.51% quarter-over-quarter from 307.7% in Q4 2025.

LENZ Therapeutics (LENZ) EBITDA Margin (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has reported EBITDA Margin for 2 consecutive years, with 2321.67% the latest figure, recorded in Q1 2026.

In Q1 2026, EBITDA Margin changed N/A year-over-year to 2321.67%; the TTM figure through Mar 2026 stood at 1714.85% (changed N/A YoY), while the FY2025 annual figure was 1822.76%, changed N/A from the prior year.
EBITDA Margin slipped to 2321.67% in Q1 2026 per LENZ's latest filing, from 307.7% in the prior quarter.
Across five years, EBITDA Margin topped out at 307.7% in Q4 2025 and bottomed at 2321.67% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	LENZ Therapeutics	146.20 Mn	146.20 Mn	5.21 Mn	-622.89%

Download Data